The asthma treatment guidelines have seen several new treatment options added in the past years, particularly for severe asthma- in which T2 biologicals form an important new class of add-on therapeutics. Despite these recent additions, only a sub-population of severe asthmatics are responsive to these new biologics and an unmet clinical need remains- particularly as it pertains to inflammation and re-modelling in severe asthma.
This collection will address potential new mechanisms and therapeutic targets for asthma in an explorative fashion, with the aim of paving the way for a new generation of pharmacological or non-pharmacological treatments. This will be achieved by highlighting mechanisms of inflammation and remodeling in asthma, and by reviewing key ongoing developments in asthma pharmacology.
The asthma treatment guidelines have seen several new treatment options added in the past years, particularly for severe asthma- in which T2 biologicals form an important new class of add-on therapeutics. Despite these recent additions, only a sub-population of severe asthmatics are responsive to these new biologics and an unmet clinical need remains- particularly as it pertains to inflammation and re-modelling in severe asthma.
This collection will address potential new mechanisms and therapeutic targets for asthma in an explorative fashion, with the aim of paving the way for a new generation of pharmacological or non-pharmacological treatments. This will be achieved by highlighting mechanisms of inflammation and remodeling in asthma, and by reviewing key ongoing developments in asthma pharmacology.